News
Zacks Investment Research on MSN16h
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate CancerJohnson & Johnson JNJ announced positive top-line data from a late-stage study evaluating the combination of niraparib, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback